John Rim, Samsung Biologics CEO

Af­ter a ban­ner year, Sam­sung will charge for­ward with 'su­per plan­t' plans, and look to ex­pand abroad

Sam­sung Bi­o­log­ics’ fu­ture plans in­volve a lot of big, im­por­tant, ex­pen­sive build­ings. And now, the com­pa­ny re­vealed in its Q4 earn­ings meet­ing, sev­er­al of those ex­pen­sive build­ings, part of a mas­sive “su­per plant,” will fea­ture a heavy em­pha­sis on mR­NA, as the suc­cess and de­mand for Covid-19 vac­cines con­tin­ue to pay off.

Plant 5, the most re­cent­ly an­nounced build­ing of its $2 bil­lion “su­per plant,” will fea­ture mul­ti-modal mR­NA, pDNA and vi­ral vec­tor prod­uct ser­vices, in ad­di­tion to cell and gene ther­a­pies. That will be in ad­di­tion to a vac­cine drug sub­stance man­u­fac­tur­ing suite that’s ex­pect­ed to be ready to go at the al­ready-erect­ed fa­cil­i­ties in Song­do with­in the “ear­li­er part of this year,” Sam­sung said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.